Brian M. Silver is CFO at TScan Therapeutics, Inc. (TCRX). They have made 5 open-market trades across 1 company since 2021, most recently 2022-12-28.
CIK 0001860597
5 open-market purchases totalling $157K since 2021, never a sale. Across 5 scored buys the stock is down 7.1% at ninety days, and 7.6 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| TCRX | 32,885 | $8K |
Shares reported on the most recent Form 4, priced at the 2022-12-29 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 20% |
| Avg Move | +3.2% | -3.0% | -7.1% |
| Alpha | +3.5% | -2.6% | -7.6% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TCRX | BUY | 2022-12-27 | 2022-12-29 | $1.53 | $9K | +2.3% | +5.2% | +49.7% |
| TCRX | BUY | 2022-03-24 | 2022-03-28 | $3.40 | $51K | -15.2% | -28.3% | -1.4% |
| TCRX | BUY | 2021-09-21 | 2021-09-22 | $6.32 | $32K | +27.7% | +17.1% | -26.9% |
| TCRX | BUY | 2021-09-09 | 2021-09-13 | $8.48 | $50K | -2.5% | -14.1% | -24.7% |
| TCRX | BUY | 2021-07-20 | 2021-07-22 | $15.00 | $15K | +3.9% | +5.3% | -32.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.